[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study]
- PMID: 19156087
[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study]
Abstract
The most effective symptomatic treatment for Parkinson's disease (PD) is levodopa/dopa decarboxylase (DDC)-inhibitor or conventional levodopa. However, after a few years of treatment, motor complications may develop, such as <<wearing-off>> and dyskinesias. Symptoms of <<wearing-off>> can be both motor symptoms, e.g. tremor and bradykinesia, as well as non-motor symptoms (pain, mood changes and anxiety). The development of these complications may affect the patients quality of life (QOL). To investigate the efficacy and safety direct switch from conventional levodopa to stalevo(levodopa/carbidopa/entacapone) in PD patients with fluctuations and dyskinesias.
Methods/patients: Thirty four patients with PD were recruited in the study. The mean age (+/-SD) of the patients was 64,5+/-8,3 years, the mean duration of PD (+/-SD) was 5,9+/-3,1 years, the mean H&Y was 2,5+/-0,5. All patients experienced fluctuations and six had dyskinesias (one patient had biphasic dyskinesias with painful dystonia). The mean baseline levodopa dose was 785,8+/-150,2 mg per day taking in three to six doses. Assessments were performed before, end of 1, 4 and 12 weeks of treatment period and consisted of Hoen/Yahr stages (H&Y), II and III parts of the Unified Parkinson's Disease Rating Scale (UPDRS), patients diaries with registration <<on-off>> periods, scale EQ-5D, WOQ-9. While switching from conventional levodopa to stalevo taking single levodopa doses were equivalent or less. Maximum allowed doses of stalevo were four times per day.
Results: Direct switch to stalevo results in improvement of motor and non-motor symptoms (pain and anxiety) in fluctuating patients and significant prolongation of <<on>> periods (p<0.01). We observed dramatic improvement biphasic dyskinesias with painful dystonia and reducing severity of dyskinesias in others patients. Improvement was seen in QOL by scale EQ-5D from 10,7+/-1,9 to 8,6+/-2,1 points (p<0,05). Conclusions. Switching from conventional levodopa to stalevo is efficacy and safety and can significantly improve QOL PD patients with fluctuations and dyskinesias.
Similar articles
-
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.Eur Neurol. 2005;53(4):197-202. doi: 10.1159/000086479. Epub 2005 Jun 20. Eur Neurol. 2005. PMID: 15970632 Clinical Trial.
-
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.J Neural Transm (Vienna). 2005 Feb;112(2):221-30. doi: 10.1007/s00702-004-0184-1. Epub 2004 Oct 22. J Neural Transm (Vienna). 2005. PMID: 15503197 Clinical Trial.
-
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878. Mov Disord. 2009. PMID: 18846551 Clinical Trial.
-
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Expert Rev Neurother. 2012 Feb;12(2):119-31. doi: 10.1586/ern.11.203. Expert Rev Neurother. 2012. PMID: 22288667 Review.
-
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7 Pt 2):62-8. Zh Nevrol Psikhiatr Im S S Korsakova. 2013. PMID: 23994933 Review. Russian.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical